The company's lead program CRG-023 is a tri-specific CAR T designed to target multiple B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector. CARGO continues advancing CRG-023 into Phase 1 trials and is developing its allogeneic platform while evaluating strategic options.
Cyborg Score Rationale
The company discontinued FIRCE-1, its Phase 2 clinical study of firi-cel after data from 51 patients showed concerning safety issues with 18% developing severe immune complications despite a 77% overall response rate. CARGO implemented a 50% workforce reduction to preserve cash and subsequently executed a 90% reduction in force, indicating significant operational distress and pivot in strategic direction.
Top Insights
Lead program (firi-cel) discontinued due to unfavorable benefit-risk profile with severe safety signals; company pivoting focus to CRG-023
Executed drastic workforce reduction from initial 50% down to 90% RIF, indicating preserved cash runway through 2028 but reduced operational capacity
As of August 2025, market capitalization collapsed to $216M with stock trading at $4.47, down sharply from IPO and peak valuations
Remains pre-revenue as clinical-stage company with focus on addressing limitations in existing CAR T therapies for cancer patients
Named Competitors
Allogene Therapeutics — Allogeneic CAR T-cell therapies for cancer
Kyverna — CAR T-cell therapy developer
Juno Therapeutics — Cell therapy platform including CAR T
Recent Developments
(July 2025) Announced further 90% workforce reduction following firi-cel program suspension
(January 2025) Discontinued FIRCE-1 Phase 2 study due to safety concerns; 50% workforce reduction announced
(January 2025) CRG-023 Phase 1 dose escalation study enrollment on track for Q2 2025 initiation
Open the full interactive CARGO Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.